BridgeBio Pharma, Inc.NASDAQ: BBIO

BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

· Issued by BridgeBio Pharma, Inc.

On 6ix: 6ix.com/news/bridgebio-pharma-announces-publication-of-positive-results-from-phase-3-attribute-cm

Watch BridgeBio Pharma's latest callBridgebio Pharma (NASDAQ:BBIO) Q2 2026 Earnings Call · Replay · Aug 10Read the transcript of Bridgebio Pharma (NASDAQ:BBIO) Q2 2026 Earnings Call
BridgeBio Pharma's next earnings callBridgebio Pharma (NASDAQ:BBIO) Q3 2026 Earnings Call · Oct 29, 2026 at 4:30 PM EDTRegister

- ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p

BridgeBio Pharma, Inc. on 6ix

Story so far

Earlier from BridgeBio Pharma

Later from BridgeBio Pharma

All BridgeBio Pharma news releases